ArticleScientific reports2023

Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice.

Dennis Horvath et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.